semaglutide with tirzepatide vs for Weight Loss What Are the Side Effects

#GLP1 #ObesityManagement #Type2Diabetes #Pharmacology #ClinicalResearch #PatientEducation #HealthcareInnovation #Endocrinology #WeightManagement #MedicalEducation Oral GLP-1 Therapy Advancements in Obesity and Diabetes The future of GLP-1 therapy may become much simpler for patients

Any adjustment to treatment is a decision for the prescriber

The meta-analysis found that SGLT2 inhibitors were associated with a 10% reduced risk of major adverse cardiovascular events, a 22% reduced risk of heart failure or cardiovascular death, and a 38% risk reduction in a composite of adverse kidney outcomes (Inzucchi 2021)

These numbers can vary